Table 2.
EPO and IGF1 concentration in the serum of neonatal CP patients
Variable | Allogeneic | Autologous | p-valuea | ||
---|---|---|---|---|---|
| |||||
N | Mean±S.E | N | Mean±S.E | ||
| |||||
EPO | |||||
EPO pre | 3 | 59.07±11.51 | 4 | 44.9±14.01 | |
EPO post | 3 | 110.5±84.75 | 4 | 77.5±17.63 | |
Difference | 3 | -51.43±78.09 | 4 | -32.6±6.95 | 0.59 |
IGF-1 | |||||
IGF-1 pre | 2 | 56.4±30.2 | 4 | 79.18±36.73 | |
IGF-1 post | 3 | 49.3±24.3 | 4 | 82.63±40.06 | |
Difference | 2 | -5.05±6.25 | 4 | -3.45±3.57 | 1 |
aWilcoxon rank sum test.